Assessing the risk of recurrence of luminal HER2-negative breast cancer and the possibility of intensifying adjuvant hormonal therapy to reduce the risk of progression

Gordeeva O.O.

Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia

The basis of treatment for luminal HER2-negative breast cancer (BC), the most common subtype of BC, is hormonal therapy, which is prescribed for 5–10 years after radical treatment. Despite such long-term treatment, one in 3–4 patients with stage II and one in 2–3 patients with stage III experience a relapse, which can occur within 20 years after the initial diagnosis. The risk of recurrence depends on such tumor characteristics as the degree of malignancy, the level of proliferative activity, the extent of regional lymph node involvement, etc. In order to reduce this risk, several strategies for intensifying adjuvant hormonal therapy are currently used. These include ovarian suppression, prolonged hormonal therapy, and the use of CDK4/6 inhibitors. This article provides an overview of the risk factors for recurrence and currently available strategies for adjuvant hormonal therapy.

Keywords

About the Authors

Corresponding author: Olga O. Gordeeva, Cand. Sci. (Med.), Medical Oncologist, Head of the Outpatient Department, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia; Gordeeva.oo@yandex.ru; ORCID: https://orcid.org/0000-0002-8266-0218

Similar Articles